Navigation Links
Ellex Announces Six-Month Results on Retina Regeneration Therapy
Date:11/9/2008

ATLANTA, Nov. 9 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT(TM)) at the annual meeting of the American Academy of Ophthalmology. The results were presented by Professor John Marshall, PhD, FRCPath, FRCOphth (Hons), of St. Thomas' Hospital, London, under whom the study has been conducted.

The six-month results show that Ellex 2RT is clinically safe and effective in the treatment of macular edema secondary to diabetic retinopathy.

"This is a revolutionary treatment because, for the first time, we can obtain all the therapeutic benefits seen with earlier laser treatments, but without the collateral damage," said Professor Marshall.

"Currently, this is the mildest laser therapy to be tested in a clinical setting which has demonstrated a selective and therapeutic effect on the retinal pigment epithelium (RPE)."

Ellex 2RT uses a custom designed, Q-switched green YAG laser that produces very precise, three-nanosecond pulses of 532nm light energy. The laser was developed specifically for Ellex 2RT by the Ellex Advanced Research Team in Adelaide, Australia.

About The Clinical Study

In the clinical study conducted at St. Thomas' Hospital in London, 23 patients (38 eyes) with newly-diagnosed diabetic maculopathy were recruited and treated with Ellex 2RT. Seventeen patients (28 eyes) completed the six-month follow-up examination.

Patients underwent treatment using the Ellex 2RT laser to deliver a modified macular grid pattern, guided by fluorescein angiography.

Retinal changes: Six months after laser treatment, 46 percent of patients had a decrease in their central macular thickness by more than 5 percent from baseline. The central macular thickness remained stable in 39 percent of patients and increased by more than 5 percent in only 15 percent of

patients. In addition, the amount of hard exudates also decreased in more than half of the treated eyes. Visual acuity results: At six months, 43 percent of eyes had an improvement of two or more lines of LogMar visual acuity, while 28 percent showed an improvement of one to two lines of visual acuity.

The visual acuity remained stable in 15 percent of eyes and deteriorated in 14 percent of eyes.

"The six-month results presented at the AAO by Professor Marshall confirm our belief that there is a way to successfully treat diabetic macular edema safely and effectively without a significant visual trade-off," said Simon Luscombe, Ellex CEO. "Our next step is to expand clinical studies to investigate the therapeutic role of Ellex 2RT in other diseases that impact the retinal pigment epithelium, including early Age-Related Macular Degeneration (AMD), drusen and central serous retinopathy."

Ellex confirmed that it has commenced trials in Australia to further validate the effectiveness of Ellex 2RT. This includes double blind randomized control studies for treating Diabetic Macula Edema and Diabetic Retinopathy in conjunction with the South Australian Institute of Ophthalmology and the Royal Adelaide Hospital. An early AMD trial is also planned with the Royal Victorian Eye and Ear Hospital. Results from these trials are expected to be available in the second half of FY09. Further trials are also planned for London.

ABOUT ELLEX 2RT RESEARCH

Ellex 2RT research is funded in part by an A$1.9 million, two-year Commercial Ready Grant awarded to Ellex by the Australian Government to support the development of a new and innovative laser therapy for the treatment of Age-Related Macular Degeneration (AMD) and other retinal diseases. The grant was applied for in order to expand laboratory and clinical research in Australia based on proof- of-principle laboratory work conducted at St. Thomas' Hospital in London under the direction of Professor Marshall.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) designs, manufactures and sells a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye diseases. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound devices for ophthalmology, initiating the expansion of its product line beyond lasers. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and treat the leading causes of blindness.

For additional information about Ellex and its products, please visit http://www.ellex.com.


'/>"/>
SOURCE Ellex Medical Lasers Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
2. Ellex Commences Direct Sales in Germany
3. Ellex to Preview New Multi-Color Photocoagulation Laser at AAO
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 ... ... Inc. , a full-service health care communications company offering education, research and ... resource for practitioners and specialists working in infectious diseases. , As the ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... tracking solution, The Guard, to associations of medical professionals throughout the country. The ... including security risk assessments, policies and procedures, employee training, regulatory updates, and compliance ...
(Date:2/10/2016)... ... 10, 2016 , ... 10 Best Water is excited to announce ... brand owners that topped the list as a result of their commitment to offering ... brand was Tibet 5100, a top notch water company that specializes in providing the ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... Feb. 10, 2016 Urologix, the market leader ... of Benign Prostatic Hyperplasia (BPH), announces new private ownership ... , a medical device industry veteran of more than ... Liability Company.  Plymouth, Minn. ... Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue to ...
(Date:2/10/2016)... February 10, 2016 A Worldwide Clinical ... be held at Victoria Park Plaza in London ... seminar on technology and future advances for late phase research ... Lorna Graham , associate director of project management at ... up with new regulations and standards in late phase research. ...
Breaking Medicine Technology: